Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 175-184

  Zhang, Yan ^a,b   Luo, Hui Yan ^a,c   Liu, Guang Lin ^d   Wang, De Shen ^a   Wang, Zhi Qiang ^a   Zeng, Zhao Lei ^a   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Gemcitabine; Pancreatic cancer; PPAR ; Prognosis

Indexed keywords

DEOXYCYTIDINE; FLUOROURACIL; GEMCITABINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR CELL CULTURE; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PPAR GAMMA; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84917729629     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2709     Document Type: Article

References (45)

1. Pliarchopoulou K and Pectasides D: Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev 35: 431-436, 2009.
2. Ramon Torrell JM and Serra Majem L: Descriptive epidemiology of cancer of the stomach in Catalonia (1983-1986). Gac Sanit 4: 76-77, 1990 (In Spanish).
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
4. Bardeesy N and DePinho RA: Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909, 2002.
5. Michalik L, Auwerx J, Berger JP, et al: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58: 726-741, 2006.
6. Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature 405: 421-424, 2000.
7. Zhu YJ, Crawford SE, Stellmach V, et al: Coactivator PRIP, the peroxisome proliferator-activated receptor-interacting protein, is a modulator of placental, cardiac, hepatic, and embryonic development. J Biol Chem 278: 1986-1990, 2003.
8. Lemberger T, Desvergne B and Wahli W: Peroxisome proliferator- activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 12: 335-363, 1996.
9. Auboeuf D, Rieusset J, Fajas L, et al: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46: 1319-1327, 1997.
10. Kliewer SA, Forman BM, Blumberg B, et al: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355-7359, 1994.
11. Bishop-Bailey D and Hla T: Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 274: 17042-17048, 1999.
12. Xin X, Yang S, Kowalski J and Gerritsen ME: Peroxisome proliferator- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274: 9116-9121, 1999.
13. Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA and Capone JP: Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proc Natl Acad Sci USA 90: 5723-5727, 1993.
14. Kliewer SA, Umesono K, Mangelsdorf DJ and Evans RM: Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355: 446-449, 1992.
15. Ramachandran L, Manu KA, Shanmugam MK, et al: Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferatoractivated receptor gamma activation pathway in gastric cancer. J Biol Chem 287: 38028-38040, 2012.
16. Bishop-Bailey D: PPARs and angiogenesis. Biochem Soc Trans 39: 1601-1605, 2011.
17. Jung UJ, Torrejon C, Chang CL, Hamai H, Worgall TS and Deckelbaum RJ: Fatty acids regulate endothelial lipase and inflammatory markers in macrophages and in mouse aorta: a role for PPARgamma. Arterioscler Thromb Vasc Biol 32: 2929-2937, 2012.
18. Tontonoz P, Hu E and Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156, 1994.
19. Gelman L, Fruchart JC and Auwerx J: An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 55: 932-943, 1999.
20. Fajas L, Debril MB and Auwerx J: Peroxisome proliferatoractivated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 27: 1-9, 2001.
21. Wang T, Xu J, Yu X, Yang R and Han ZC: Peroxisome proliferator- activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 58: 1-14, 2006.
22. Kristiansen G, Jacob J, Buckendahl AC, et al: Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 12: 6444-6451, 2006.
23. Watkins G, Douglas-Jones A, Mansel RE and Jiang WG: The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer. Oncol Rep 12: 483-488, 2004.
24. Segawa Y, Yoshimura R, Hase T, et al: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 51: 108-116, 2002.
25. Theocharis S, Kanelli H, Politi E, et al: Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 36: 249-255, 2002.
26. Zhang GY, Ahmed N, Riley C, et al: Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer 92: 113-119, 2005.
27. Sasaki T, Fujimoto Y, Tsuchida A, Kawasaki Y, Kuwada Y and Chayama K: Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer. Pathobiology 69: 258-265, 2001.
28. Hahn WC, Dessain SK, Brooks MW, et al: Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 22: 2111-2123, 2002.
29. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M and Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10: 8465-8471, 2004.
30. Asou H, Verbeek W, Williamson E, et al: Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol 15: 1027-1031, 1999.
31. Zang C, Liu H, Posch MG, et al: Peroxisome proliferatoractivated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk Res 28: 387-397, 2004.
32. Sato H, Ishihara S, Kawashima K, et al: Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 83: 1394-1400, 2000.
33. Sarraf P, Mueller E, Smith WM, et al: Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3: 799-804, 1999.
34. Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465-470, 1998.
35. Ogino S, Shima K, Baba Y, et al: Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136: 1242-1250, 2009.
36. Inoue K, Kawahito Y, Tsubouchi Y, et al: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 287: 727-732, 2001.
37. Eibl G, Wente MN, Reber HA and Hines OJ: Peroxisome proliferator- activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun 287: 522-529, 2001.
38. Farrow B and Evers BM: Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 301: 50-53, 2003.
39. Itami A, Watanabe G, Shimada Y, et al: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer 94: 370-376, 2001.
40. Katz MH, Fleming JB, Lee JE and Pisters PW: Current status of adjuvant therapy for pancreatic cancer. Oncologist 15: 1205-1213, 2010.
41. Squadroni M and Fazio N: Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci 14: 386-394, 2010.
42. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10: 2307-2318, 2004.
43. Leung L, Radulovich N, Zhu CQ, et al: Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One 7: e46677, 2012.
44. Awasthi N, Zhang C, Ruan W, Schwarz MA and Schwarz RE: BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther 11: 2644-2653, 2012.
45. Wang H, Pei W, Luan Q, et al: A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA. Cancer Biol Ther 13: 712-719, 2012.